Clinical trials
Immunization clinical trials
Below are recruiting immunization clinical trials, each written for real people, not researchers. We’re tracking 1,059 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05139706Recruiting
Study immune side effects after cancer immunotherapy
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
Montreal, QuebecAges 18–100 - NCT05214391RecruitingPhase 2
Zanubrutinib for chronic immune low platelets after prior treatments
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05277129Recruiting
Study of the immune response soon after stroke
This study looks at how your body’s immune system reacts in the first hours after a stroke. It may help researchers understand stroke-related immune changes and improve future treatments.
LørenskogAges 18 years+ - NCT05306925Recruiting
Arginine supplement study for newborns after major gut surgery
This study looks at whether giving an amino-acid supplement called arginine to newborns after major bowel surgery can improve the baby’s immune response. It may help doctors understand how to support recovery after conditions like necrotizing enterocolitis or certain birth defects.
Liverpool, MerseysideAges 5 months–10 months - NCT05318196Recruiting
Predict kidney disease risk and progression from patient data
This trial looks at ways to predict how kidney disease may develop, change, or cause complications using information from patients. It may help doctors identify people at higher risk and tailor care earlier.
ToulouseAges 18–99 - NCT05338190RecruitingPhase 3
Belimumab added to rituximab for chronic immune thrombocytopenia
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
CréteilAges 18 years+ - NCT05354765Recruiting
Collect immune cells by lymphapheresis to study cancer response
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
ParisAges 18 years+ - NCT05377307Recruiting
Long-term follow-up for gene-edited immune cell therapy
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Kaohsiung, TaiwanAges Any age - NCT05421325RecruitingPhase 2
Vaccine-like immune treatment to prevent lung infections in seniors
This Phase 2 study tests a site-specific immune “booster” in people age 65 and older to help improve natural immunity and reduce respiratory (lung/airway) infections. You may be eligible if you can consent, are in an eligible living situation, and are not currently using certain immune-suppressing medicines.
Burnaby, British ColumbiaAges 65 years+ - NCT05442710RecruitingPhase 2
Immune cell treatment for recovery from severe septic shock
This trial tests an immune-cell treatment given outside the body to help people recover from septic shock, a life-threatening reaction to infection. It aims to improve survival and organ recovery in patients who are still very ill despite standard care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT05507242RecruitingPhase 2
Drug that blocks TSLP to reduce COPD flare airway inflammation
This Phase 2 trial tests whether blocking TSLP can reduce inflammation in the airways of people with COPD, especially around flare-ups. If you often need prednisone and/or antibiotics for COPD exacerbations, this study may help determine a new treatment approach.
CopenhagenAges 40 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05584488Recruiting
Study of immune and allergy patterns over time
This study follows people with suspected or known inherited immune/allergy problems by collecting health information and blood. It may help researchers understand how immune systems and allergies behave over time and support future studies.
New York, New YorkAges Up to 99 years - NCT05599880RecruitingPhase 2
Bortezomib for adults with hard-to-treat immune low platelets
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
Guri-siAges 19 years+ - NCT05648136Recruiting
Blood test study for immune markers in miscarriage and IVF failure
This study looks at immune-related blood patterns and other measurements to better understand why some women have repeated pregnancy loss or repeated IVF implantation failure. If you qualify, your answers and test results may help researchers identify biomarkers that could guide future care.
Amiens, PicardieAges 18–39 - NCT05667610Recruiting
Immune and gut diet study for peanut-allergic children
This trial studies whether an immune-supportive diet can improve gut health (gut permeability) in children with confirmed peanut or tree-nut allergy. If you join, the researchers will use allergy testing and gut-related diet approaches to see whether symptoms and gut measures change.
AmsterdamAges 3–17 - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT05774093Recruiting
Study how COVID immunity affects reinfection risk
This study looks at how well COVID-19 protection (immune barrier) holds up over time and how likely people are to get reinfected. It may help researchers understand who is more at risk after prior infection and why.
Guangzhou, GuangdongAges Any age - NCT05799898Recruiting
Fast heart and vessel check for people on immune cancer drugs
This trial looks at a faster heart and blood-vessel assessment for people who are taking immune cancer drugs and have been referred because they might be having a heart-related side effect. It may help by speeding up evaluation and treatment decisions when symptoms raise concern.
ParisAges 18 years+ - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT05878977Recruiting
Testing biomarkers in immunotherapy for advanced melanoma
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
LjubljanaAges 18 years+ - NCT05931718Recruiting
Track diagnosis and treatment in autoimmune blood count disorders
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
MilanAges 18 years+ - NCT05941741RecruitingPhase 3
Tested low-dose radiation plus cadonilimab for nasopharyngeal cancer
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Guangzhou, GuangdongAges 18–70
Hear when a new Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunization?
- Yes. Clin2 currently lists 1,059 recruiting immunization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.